Read the May 2017 ASBMT eNews - NEW FORMAT!


ASBMT's eNews, president's message and news bulletins will keep you up to date on the latest developments in the HCT field.  

Read the May 2017 ASBMT eNews below! 

May 2017

  Download the entire issue here in PDF format.  Selected stories below . . .  

Policy Perspectives: 
Medicare Proposed FY18 Inpatient Rule Very Problematic for Autologous Transplant; Comments Needed
By Stephanie Farnia, ASBMT Director of Health Policy and Strategic Relations

April kicks off the beginning of the Medicare (CMS) rule-making season. As a Federal Agency charged with the role of implementing health care legislation, CMS enters a lengthy process each year of creating the new Inpatient Prospective Payment System (IPPS) Final Rule – a set of very detailed instructions, payment procedures and calculations for the upcoming Fiscal (FY) or Calendar Year (CY).  ...Each year, the ASBMT and NMDP partner to attempt to get health professionals and transplant programs to comment on the proposed rule. This is not a fruitless endeavor – the positive changes you have seen in your reimbursement, including the splits to the Autologous and Allogeneic DRGs and the dramatic increase in the outpatient payment rate for 2017, are due to the efforts of yourselves and your colleagues in sending comments to CMS. Due to the potential impact of the proposed changes for FY18, we will need all of you to comment on the issues of concern this year. READ MORE

A Word from President Krishna Komanduri, MD
It will come as no surprise that both FACT and ASBMT are considering the increasingly important place of T cell therapies in the transplantation and cellular therapy landscape. Indeed, the last month was marked by landmark FDA Biologics License Application (BLA) filings by two companies for chimeric antigen receptor T cell (CAR-T) therapies for CD19-expressing leukemia and lymphoma. While no one I know possesses a (functioning) crystal ball, it certainly seems possible that we may see an approval of one or more T cell therapies for cancer before the end of the year. READ MORE

ASBMT Launches Facebook Page

Are you on Facebook more often than you’d like to admit? Are you “not really that into Twitter”? Are you perhaps guilty of not reading ASBMT’s eNews cover-to-cover on a regular basis? Well, then we have some good news for you! The ASBMT has quietly launched a Facebook page, that will allow you to keep your finger on the pulse of all things ASBMT – right there in your Facebook feed. READ MORE

Pharmacy SIG 2017 New Investigator Research Award
Request for Letter of Intent (LOI)

The ASBMT is excited to announce that we are accepting applications for the ASBMT Pharmacy SIG New Investigator Research Award. Interested applicants are required to submit a Letter of Intent (LOI). The LOI should follow the format below and will serve to permit assessment of eligibility for the award. Letters of Intent must be received by e-mail to the administrator of the grant, no later than Friday, June 2, 2017 (5:00 pm CST). For full instructions, please CLICK HERE.


FACT Update
Feedback on Hematopoietic Cell Therapy Standards Requested

The Foundation for the Accreditation of Cellular Therapy (FACT) and the Joint Accreditation Committee of ISCT-EBMT (JACIE) have published the draft 7th edition of the FACT-JACIE International Standards for Hematopoietic Cellular Therapy Product Collection, Processing, and Administration for inspection and public comment for a 90-day period. Comments will be accepted from May 1, 2017 through July 30, 2017. READ MORE.


Also in this issue. . . 

  Download the entire issue here in PDF format.   




View the eNews archive



Other ASBMT News Sources: 






Publication Scheduled Date